hexamethonium has been researched along with Arteriosclerosis Obliterans in 1 studies
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
Arteriosclerosis Obliterans: Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| WINDESHEIM, JH | 1 |
| ROTH, GM | 1 |
| GIFFORD, RW | 1 |
1 other study available for hexamethonium and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
The use of hexamethonium in treatment of arteriosclerosis obliterans.
Topics: Arteriosclerosis; Arteriosclerosis Obliterans; Cardiovascular Agents; Hexamethonium; Humans; Muscle | 1955 |